At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Advancing Research with the goal of delivering life-changing solutions for people with MS.
More than 2.5 million people around the world live with multiple sclerosis (MS), an autoimmune, neuroinflammatory disease. Despite progress in our understanding of the disease, treating MS remains a challenge.
Celgene is committed to advancing research to deliver life-changing solutions for people with MS. Our teams and experts in the field share their excitement for what we’re doing now and what lies ahead for this complex disease and global community.
Advocacy & Collaboration
Celgene and our advocacy partners collaborate to bring hope to the fight against MS.
See a list of MS groups.
Celgene is committed to advancing research to change the lives of patients with MS.
Celgene is dedicated to offering support to patients with MS and those that care for them. Stay tuned for updates in the near future.